Autem Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Autem Therapeutics - overview
Established
2017
Location
Hanover, NH, US
Primary Industry
Medical Devices & Equipment
About
Based in New Hampshire, US, and founded in 2017 by CEO Michael Choukas, and CSO Frederico Costa, Autem Therapeutics LLC is developing a novel bioelectric oncology treatment platform to deliver low-level, amplitude-modulated electromagnetic (EM) frequency for the treatment of hepatocellular carcinoma (HCC) and other solid tumor cancers. In June 2022, Autem Therapeutics raised USD 10 million in a Series A funding led by Zentynel Frontier Investments. As of July 2022, Michael Choukas is the CEO of Autem Therapeutics. The company provides AutEMsys, a therapy that delivers personalized, amplitude-modulated electromagnetic (EM) frequencies to patients systemically to shrink tumors as well as enhance the quality of life and extend survival in early and advanced stage patient populations.
Autem Therapeutics plans to use its proceeds from July 2022 funding for the completion of its technology and related validation and testing, approvals to initiate clinical trials, European and Latin American regulatory, and US FDA Investigational Device Exemption (IDE) submissions, and the start-up phase of the HCC pivotal trial.
Current Investors
Zentynel Frontier Investments
Primary Industry
Medical Devices & Equipment
Sub Industries
Biotechnology, Oncology/Cancer Treatment, Medical Devices & Equipment
Website
www.autemtherapeutics.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.